We ensure high-quality respiratory medicines reach those who need them most. We are pioneers in pharmaceutical development, proud manufacturers of "World First" innovations in fields including tuberculosis and lung cancer.

Respiratory diseases are a major and increasing global health challenge. Chronic respiratory diseases (CRDs), including COPD, Asthma, Tuberculosis, and various infections, are leading causes of disability and death worldwide.
The total number of COPD cases globally is expected to approach 600 million by 2050, with the highest increase anticipated in low- and middle-income countries (LMICs).
India bears a significant share of global respiratory diseases. With an ageing population due to demographic shifts, the country faces health concerns like increasing chronic lung diseases.
Studies show an overall prevalence of 4.38% for Asthma and 2.1% for COPD among Indian individuals aged 45 years and above.
Environmental and lifestyle factors critically influence the rise in respiratory ailments. Rapid urbanisation and industrialisation have led to increased levels of indoor and outdoor air pollution. Chronic lung diseases like Asthma and COPD are associated with significant age-related complications, including functional geriatric syndromes such as limitations in Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), and Falls.
Focused portfolio: Empowering every breath
Cadila Pharma brings a robust portfolio of high-quality products, meticulously developed through dedicated research to address a spectrum of respiratory needs, from chronic management to acute infections.





Brand names are for reference purpose only and shall not be treated as an advertisement. Please consult a registered medical practitioner before taking any medication.
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved